SCHEDULE 13G/A: Armistice Capital and Steven Boyd Disclose 9.99% Stake in Dermata Therapeutics

Armistice Capital, LLC and its managing member Steven Boyd have disclosed a beneficial ownership of 9.99% of Dermata Therapeutics, Inc.'s common stock as of March 31, 2025, held through Armistice Capital Master Fund Ltd.

Summary

• Armistice Capital, LLC and Steven Boyd, collectively referred to as the "Reporting Persons," have filed an Amendment No. 3 to Schedule 13G regarding their beneficial ownership in Dermata Therapeutics, Inc.
• As of March 31, 2025, the Reporting Persons beneficially own an aggregate of 1,065,076 shares of Dermata Therapeutics, Inc. common stock.
• This ownership represents 9.99% of the total outstanding common stock of Dermata Therapeutics, Inc.
• Armistice Capital, LLC, as the investment manager of Armistice Capital Master Fund Ltd. (the direct holder of the shares), exercises shared voting and dispositive power over these securities.
• Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual, regulatory disclosure of beneficial ownership and does not convey positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The disclosure of a significant 9.99% stake by Armistice Capital and Steven Boyd indicates a notable institutional interest in Dermata Therapeutics, which could be viewed positively by other investors.

Key Dates

Keywords

Dermata Therapeutics, Armistice Capital, Steven Boyd, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Institutional Investor